• Firebrick raises $1.4 million through share placement
• Funds to be used for expanding Nasodine sales in US, Singapore, and Southeast Asia
• Developing up to 3 new Nasodine-branded products for launch in FY2026

Firebrick Pharma Limited (ASX:FRE) has announced that it has secured firm commitments from investors for approximately $1.4 million through the issue of 22,222,222 new fully paid ordinary shares at an issue price of $0.063 per share. This placement will allow the company to proceed with the following key projects: expanding Nasodine Nasal Spray sales in the US market, expanding Nasodine distribution and marketing in Singapore and launching it in other Southeast Asian markets during FY2026, and funding the final development and manufacturing of up to three new Nasodine-brand products for launch into all available markets in FY2026. The placement was introduced by an existing shareholder and did not incur any broker or adviser fees. The terms of the placement, including the offer price, options provided, and option exercise price and expiry, were the same as those offered in the company's previous $0.2 million placement in June 2025. The 22,222,222 new shares represent approximately 9.7% of Firebrick's current shares on issue and will be issued under the company's existing placement capacity.